NASDAQ:XLO Xilio Therapeutics Q3 2026 Earnings Results & Report $8.59 -0.41 (-4.58%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Xilio Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.30 versus the -$0.9350 consensus estimate, while revenue of $9.98 million topped the $4.92 million estimate by $5.06 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market OpensConference Call7:00 AM ET Xilio Therapeutics EPS ResultsActual EPS-$0.30Consensus EPS -$0.9350Beat/MissBeat by +$0.6350One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersXilio Therapeutics Revenue ResultsActual Revenue$9.98 millionExpected Revenue$4.92 millionBeat/MissBeat by +$5.06 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Xilio Therapeutics Q3 2026 Earnings FAQ Did Xilio Therapeutics beat earnings estimates for Q3 2026? Xilio Therapeutics (NASDAQ:XLO) reported earnings of -$0.30 per share for Q3 2026, beating the consensus estimate of -$0.9350. The report was announced on Tuesday, November 10, 2026. What was Xilio Therapeutics' revenue for Q3 2026? Xilio Therapeutics reported revenue of $9.98 million for Q3 2026, against a consensus estimate of $4.92 million. Xilio Therapeutics Earnings HeadlinesXilio Doses First Patient In XTX501 Cancer Trial; Plans 2027 Data Readout17 minutes ago | rttnews.comXilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesNovember 10 at 7:30 AM | globenewswire.comThe Withdrawal You'll Never See on Your StatementA proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to deliberately weaken the US dollar, making American exports cheaper. For savers, a weaker dollar can quietly reduce purchasing power even if account balances stay the same. Bishop Gold Group's free 2026 Gold IRA Guide explains how physical gold can be held inside a retirement account, including a common rollover mistake that can trigger a taxable distribution.November 10 at 1:00 AM | Bishop Gold Group (Ad)Xilio Therapeutics (XLO) Projected to Announce Quarterly Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comXilio Therapeutics (NASDAQ:XLO) Stock Price Breaks Above Two Hundred Day Moving Average - Here's WhyNovember 4, 2026 | americanbankingnews.comXilio Therapeutics to Present at the Stifel 2026 Healthcare ConferenceNovember 3, 2026 | globenewswire.comSee More Xilio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xilio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xilio Therapeutics and other key companies, straight to your email. Email Address About Xilio TherapeuticsXilio Therapeutics (NASDAQ:XLO) is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects. Xilio’s research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments. Its pipeline is intended to stimulate immune responses within solid tumors and potentially address cancers that have limited responses to existing immunotherapies. The company’s programs remain in clinical development and are subject to the risks and uncertainties associated with biotechnology research. Founded in 2020 and headquartered in Waltham, Massachusetts, Xilio Therapeutics serves the global oncology market through its drug-discovery and clinical-development activities. The company became publicly traded on the Nasdaq under the symbol XLO in 2021. Xilio is led by René Russo, who serves as president and chief executive officer.View Xilio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
